Review Article
Antioxidative Potentials of Incretin-Based Medications: A Review of Molecular Mechanisms
Table 3
Clinical evidence about the antioxidative potentials of GLP-1RA and DPP-4i.
| Treatment | Population of study | Effects | Ref. |
| Exenatide | 69 patients with T2DM | Reduced oxidative markers as MDA and oxLDL | [110] | GLP-1 | 15 patients with T1DM | Restored oxidative stress in endothelial cells, improved endothelial function | [12] | Liraglutide | 64 patients with T2DM | Provided cardioprotective effects via attenuating oxidative stress | [111] | GLP-1 | 60 patients with T2DM | Improved the palmitate-induced oxidative damages in cardiomyocytes | [113] | Liraglutide | 20 patients with T2DM | Declined oxidative markers and free radical generation | [112] |
|
|